EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Recent clinical researches and technological development in TIL therapy

Satoko Matsueda, Lei Chen, Hongmei Li, Hui Yao, Fuli Yu

Cancer Immunology, Immunotherapy · 12.09.2024 · 73 (11)

DOI: 10.1007/s00262-024-03793-4 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 12.09.2024. Verfasst von Satoko Matsueda und 4 weiteren Autor:innen. Beteiligte Einrichtung: Fresh Wind Biotechnologies USA Inc, 4502 Riverstone Blvd, STE1104, Missouri City, TX, 77459, USA. satoko.matsueda@freshwindbiotech.com. Hauptthemen laut MEDLINE: Lymphocytes, Tumor-Infiltrating, Neoplasms, Immunotherapy, Adoptive. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor-infiltrating lymphocyte (TIL) therapy represents a groundbreaking advancement in the solid cancer treatment, offering new hope to patients and their families with high response rates and long overall survival. TIL therapy involves extracting immune cells from a patient's tumor tissue, expanding them ex vivo, and infusing them back into the patient to target and eliminate cancer cells. This revolutionary approach harnesses the power of the immune system to combat cancers, ushering in a new era of T cell-based therapies along with CAR-T and TCR-therapies. In this comprehensive review, we aim to elucidate the remarkable potential of TIL therapy by delving into recent advancements in basic and clinical researches. We highlight on the evolving landscape of TIL therapy as a prominent immunotherapeutic strategy, its multifaceted applications, and the promising outcomes. Additionally, we explore the future horizons of TIL therapy, next-generation TILs, and combination therapy, to overcome the limitations and improve clinical efficacy of TIL therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphocytes, Tumor-InfiltratingNeoplasmsImmunotherapy, AdoptiveHumansAnimalsCombined Modality Therapy

Stichwörter der Autor:innen

Adoptive Cell TherapyCancer ImmunotherapyClinical ResearchSolid TumorsTechnological DevelopmentTumor-Infiltrating Lymphocyte (TIL) Therapy

Autor:innen und Institutionen

  • Fresh Wind Biotechnologies USA Inc, 4502 Riverstone Blvd, STE1104, Missouri City, TX, 77459, USA. satoko.matsueda@freshwindbiotech.com.
  • Department of Neurosurgery, Tianjin Fifth Central Hospital, Tianjin, 300450, China.
  • Department of Oncology, Qingdao University Medical School, Qinddao, 266003, China.
  • Fresh Wind Biotechnologies USA Inc, 4502 Riverstone Blvd, STE1104, Missouri City, TX, 77459, USA.

Zitieren

APA

Matsueda, S., Chen, L., Li, H., Yao, H., & Yu, F. (2024). Recent clinical researches and technological development in TIL therapy. Cancer Immunology, Immunotherapy, 73(11). https://doi.org/10.1007/s00262-024-03793-4

Vancouver

Matsueda S, Chen L, Li H, Yao H, Yu F. Recent clinical researches and technological development in TIL therapy. Cancer Immunology, Immunotherapy. 2024;73(11). doi:10.1007/s00262-024-03793-4

BibTeX
@article{Matsueda2024,
  author = {Matsueda, Satoko and Chen, Lei and Li, Hongmei and Yao, Hui and Yu, Fuli},
  title = {Recent clinical researches and technological development in TIL therapy},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2024},
  volume = {73},
  number = {11},
  doi = {10.1007/s00262-024-03793-4}
}
Kostenlos starten →